Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 11/20 | 0.43 |
| ▸ | RAB9A | P51151 | 10/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7184457 | 0.91 | MAPT (0.40) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL6177854 | 0.83 | NPC1 (0.57) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6181864 | 0.76 | MAPT (0.48) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL14592085 | 0.75 | MEN1 (0.48) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL5199273 | 0.75 | GRM5 (0.55) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5695828 | 0.75 | TGFBR1 (0.42) | NPC1RAB9AKMT2AHPGDSMN1; SMN2 | |
| SCHEMBL4065212 | 0.75 | HCAR3 (0.42) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5200109 | 0.74 | PIM1 (0.40) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL15069589 | 0.74 | NPC1 (0.50) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL4032725 | 0.73 | KDM4E (0.56) | MAPTNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | IL2, IL2RA, IL6ST | MAPT 4189/4885LMNA 3761/4885NPC1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.